Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol

Details for Australian Patent Application No. 2005278782 (hide)

Owner Torrent Pharmaceuticals Limited

Inventors Sheth, Rakesh; Nadkarni, Sunil Sadanand; Patel, Hasmukh Mathurbhai; Gupta, Vinodkumar; Attanti, Srinivasarao Veeravenkata

Agent FB Rice

Pub. Number AU-B-2005278782

PCT Pub. Number WO2006/025070

Priority 811/MUM/2004 30.07.04 IN

Filing date 1 August 2005

Wipo publication date 9 March 2006

Acceptance publication date 21 April 2011

International Classifications

C07D 407/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group

A61K 31/35 (2006.01) - having six-membered rings with one oxygen as the only ring hetero atom

A61P 9/00 (2006.01) Drugs for disorders of the cardiovascular system

Event Publications

15 February 2007 PCT application entered the National Phase

  PCT publication WO2006/025070 Priority application(s): WO2006/025070

21 April 2011 Application Accepted

  Published as AU-B-2005278782

1 March 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). This application has been accepted or advertised accepted. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005278786-Twodimensional strandnessand length-dependent separation of nucleic acid fragments

2005278781-Tricyclic pyrazole derivatives as cannabinoid receptor modulators